Targeting tetrahydrobiopterin metabolism in diabetic neuropathic pain: mechanisms, implications, and therapeutic strategies.
- 1Department of Endocrinology, Renmin Hospital of Wuhan University, Jiefang RD #238, Wuhan, 430060, China.
- 2Sheffield Teaching Hospitals and the University of Sheffield, Sheffield, UK.
- 3Department of Endocrinology, Renmin Hospital of Wuhan University, Jiefang RD #238, Wuhan, 430060, China. [email protected].
Abstract
Background
Diabetic neuropathic pain (DNP) is a debilitating complication affecting up to 50% of diabetic patients and severely impairing their quality of life. Current treatments provide limited relief and carry considerable side effects, underscoring the urgent need for novel, mechanism-based analgesics. Recent studies have identified tetrahydrobiopterin (BH4) as a crucial modulator of pain sensitivity. After nerve injury, its levels surge in injured neurons and infiltrating immune cells, amplifying pain signals via nitric oxide (NO) production, neuroinflammation, and ion channel sensitisation.Main text
This review addresses the critical translational challenge posed by the BH4 paradox in DNP: although systemic BH4 is essential for vascular and metabolic integrity and is depleted under chronic hyperglycaemia, its localised overproduction in the nervous system drives neuropathic hypersensitivity. Non-selective inhibition of the key upstream enzyme, GTP cyclohydrolase-1 (GCH1), risks systemic BH4 deficiency, impairing neurotransmitter biosynthesis and causing severe vascular and metabolic side effects. Attention has therefore turned to sepiapterin reductase (SPR), the terminal enzyme in BH4 de novo biosynthesis, as a more selective and safer target. SPR inhibition suppresses pathological BH4 overproduction in nociceptive and immune tissues while preserving physiological levels through the dihydrofolate reductase (DHFR)-mediated salvage pathway. Preclinical studies of SPR inhibitors such as sulfasalazine show analgesia with limited central nervous system side effects due to their restricted blood-brain barrier (BBB) permeability. To guide clinical application, we synthesise the biochemical, genetic, and physiological roles of BH4 in DNP, and propose a translational biomarker framework for monitoring target engagement and systemic safety in future clinical trials.Conclusion
We outline the mechanistic rationale and translational considerations for developing highly selective SPR inhibitors as a potentially better-tolerated, more selective approach for DNP and other BH4-driven chronic pain conditions. This rationale currently rests largely on genetic, preclinical, and surrogate-biomarker evidence, and no completed human trial has evaluated SPR inhibition for chronic pain. The proposed biomarker framework is therefore intended to inform trial design and dose optimisation rather than to imply current clinical readiness, as one step toward a future precision-medicine strategy for pain.
Related
- Lipid Metabolism and Ferroptosis in Cancer: Regulatory Mechanisms, Alternative Splicing, and Therapeutic Implications
- Resveratrol Modulates Bone Metabolism Through SIRT1-Mediated NF-κB Inhibition: Molecular Mechanisms and Therapeutic Implications.
- Gut Microbiota-Driven Neuroimmune Crosstalk in Ulcerative Colitis: From Mechanisms to Therapeutic Implications
- Exerkines in Cardiovascular–Kidney–Metabolic Syndrome: An Integrative Framework for Mechanisms and Therapeutic Implications—A Narrative Review
- Inflammation After Transcatheter Aortic Valve Implantation: Mechanisms, Risk Stratification, and Therapeutic Implications
BibTeX
@article{wei2026targeting,
title = {{Targeting tetrahydrobiopterin metabolism in diabetic neuropathic pain: mechanisms, implications, and therapeutic strategies.}},
author = {Zhaoyinling Wei and Dey Amarthya and Solomon Tesfaye and Ling Gao},
journal = {Journal of translational medicine},
year = {2026},
month = jul,
doi = {10.1186/s12967-026-08733-7},
url = {https://europepmc.org/article/MED/42958507},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Targeting tetrahydrobiopterin metabolism in diabetic neuropathic pain: mechanisms, implications, and therapeutic strategies.
AU - Zhaoyinling Wei
AU - Dey Amarthya
AU - Solomon Tesfaye
AU - Ling Gao
PY - 2026
DA - 2026/07/31
JO - Journal of translational medicine
DO - 10.1186/s12967-026-08733-7
UR - https://europepmc.org/article/MED/42958507
AB - Background Diabetic neuropathic pain (DNP) is a debilitating complication affecting up to 50% of diabetic patients and severely impairing their quality of life. Current treatments provide limited relief and carry considerable side effects, underscoring the urgent need for novel, mechanism-based analgesics. Recent studies have identified tetrahydrobiopterin (BH4) as a crucial modulator of pain sensitivity. After nerve injury, its levels surge in injured neurons and infiltrating immune cells, amplifying pain signals via nitric oxide (NO) production, neuroinflammation, and ion channel sensitisation.Main text This review addresses the critical translational challenge posed by the BH4 paradox in DNP: although systemic BH4 is essential for vascular and metabolic integrity and is depleted under chronic hyperglycaemia, its localised overproduction in the nervous system drives neuropathic hypersensitivity. Non-selective inhibition of the key upstream enzyme, GTP cyclohydrolase-1 (GCH1), risks systemic BH4 deficiency, impairing neurotransmitter biosynthesis and causing severe vascular and metabolic side effects. Attention has therefore turned to sepiapterin reductase (SPR), the terminal enzyme in BH4 de novo biosynthesis, as a more selective and safer target. SPR inhibition suppresses pathological BH4 overproduction in nociceptive and immune tissues while preserving physiological levels through the dihydrofolate reductase (DHFR)-mediated salvage pathway. Preclinical studies of SPR inhibitors such as sulfasalazine show analgesia with limited central nervous system side effects due to their restricted blood-brain barrier (BBB) permeability. To guide clinical application, we synthesise the biochemical, genetic, and physiological roles of BH4 in DNP, and propose a translational biomarker framework for monitoring target engagement and systemic safety in future clinical trials.Conclusion We outline the mechanistic rationale and translational considerations for developing highly selective SPR inhibitors as a potentially better-tolerated, more selective approach for DNP and other BH4-driven chronic pain conditions. This rationale currently rests largely on genetic, preclinical, and surrogate-biomarker evidence, and no completed human trial has evaluated SPR inhibition for chronic pain. The proposed biomarker framework is therefore intended to inform trial design and dose optimisation rather than to imply current clinical readiness, as one step toward a future precision-medicine strategy for pain.
SN - 1479-5876
ER -